Krystal Biotech

$60.26 0.00% ($0.00)
  • 1D
  • 1W
  • 1M
  • 1Y
  • 5Y
  • YTD

Get ready to invest


About Krystal Biotech

Krystal Biotech, Inc. is a clinical-stage gene therapy company. The Company is using its proprietary Skin TARgeted Delivery (STAR-D) platform to develop treatments for skin diseases. The Company’s products are directed to the treatment of monogenic and congenital skin diseases, including dystrophic epidermolysis bullosa (DEB) and autosomal recessive congenital ichthyosis (ARCI). DEB is an incurable, often fatal skin blistering condition caused by mutations in the gene encoding type VII collagen (COL7), a protein that provides critical structural adhesion between skin layers in a normal individual. Beremagene geperpavec (B-VEC)a replication-defective, non-integrating HSV-1 that is based on the Company's viral gene therapy platform, is the Company’s product candidate being evaluated in humans and is the subject of a planned phase III clinical trial.

Stock Analysis

last close $60.26
1-mo return -6.2%
3-mo return -3.6%
avg daily vol. 184.05T
52-week high 102.99
52-week low 38.86
market cap. $1.5B
forward pe -
annual div. -
roe -21.2%
ltg forecast -
dividend yield -
annual rev. $--
inst own. 81.5%

Subscribe now for daily local and international financial news